Tag: 300-400

Determination of Proton Pump Inhibitors by Spectrophotometric, Chromatographic and by Hyphenated Techniques: A Review was written by Joshi, Aditya A.;Nerkar, Pankaj P.. And the article was included in Critical Reviews in Analytical Chemistry in 2021.SDS of cas: 117976-90-6 The following contents are mentioned in the article:

A review. A detailed review to analyze the anti ulcer proton pump inhibitor (PPI) drugs, particularly for determination of their concentration percentage (assay) by anal. methods developed on anal. instruments i.e., UV visible Spectrophotometer, High Performance Liquid Chromatog., Ultra Performance Liquid Chromatog., and Hyphenated techniques. The review includes literature survey of PPI drugs namely omeprazole (OPZ), lansoprazole (LPZ), pantoprazole (PPZ) rabeprazole (RPZ), dexlansoprazole (DLPZ), esomeprazole (EPZ), dexrabeprazole (DRPZ), ilaprazole (IPZ), and tenatoprazole (TPZ). The examined literature survey addressed chromatog. (HPLC and UPLC) and UV visible spectrophotometric methods with LC-MS/MS methods used in pure forms, pharmaceutical formulations, and human plasma and other biol. fluids for their estimation In case of validation parameters mostly Linearity, Recovery study, LOD and LOQ was considered and mentioned. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6SDS of cas: 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).SDS of cas: 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Cooperative binding and stepwise encapsulation of drug molecules by sulfonylcalixarene-based metal-organic supercontainers was written by Sheng, Tian-Pu;Fan, Xin-Xia;Zheng, Guo-Zong;Dai, Feng-Rong;Chen, Zhong-Ning. And the article was included in Molecules in 2020.Related Products of 117976-90-6 The following contents are mentioned in the article:

The cooperative binding behavior of a face-directed octahedral metal-organic supercontainer featuring one endo cavity and six exo cavities was thoroughly examined in chloroform solution through UV-visible (UV-Vis) titration technique using two representative drug mols. as the guests. The titration curves and their nonlinear fit to Hill equation strongly suggest the efficient encapsulation of the guest mols. by the synthetic host, which exhibit interesting cooperative and stepwise binding behavior. Based on the control experiments using tetranuclear complex as a reference, it is clear that two equivalent of the guest mols. are initially encapsulated inside the endo cavity, followed by the trapping of six addnl. equivalent of the drug mols. through six exo cavities (1 equivalent per exo cavity), and the remaining guests are entrapped by the external pockets. The results provide an in-depth understanding of the cooperative binding behavior of metal-organic supercontainers, which opens up new opportunities for designing synthetic receptors for truly biomimetic functional applications. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Related Products of 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Related Products of 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Green atomic absorption spectroscopic methods for the determination of rabeprazole sodium and fluvastatin sodium in pure and pharmaceutical dosage forms was written by Kamal, Miranda F.;Morshedy, Samir;Saad, Dina A.;Moneeb, Marwa S.. And the article was included in International Research Journal of Pure and Applied Chemistry in 2021.Safety of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

Novel green anal. methods have been proposed for the assay of Rabeprazole sodium and Fluvastatin sodium in their pure and formulated dosage forms. The methods determine each drug through the estimation of its sodium content, using Flame Atomic Absorption Spectroscopy at wavelength 589 nm. Central laboratory at Faculty of Pharmacy, Damanhour University. Time duration Jan.-March, 2020. Methods are developed and optimized for maximum sensitivity, selectivity and degree of greenness. Linearity is achieved in the range of 8.29-66.33 ppm of Rabeprazole sodium (equivalent to 0.5-4 ppm Na) and 14.13-141.32 ppm of Fluvastatin sodium (equivalent to 0.75 -7.5 ppm Na). The proposed assays are fully validated regarding ICH guidelines. Atomic spectroscopic assays are compared to reported spectrophotometric ones for each drug sep. using Student t-test and F-variance ratio. Satisfactory values indicate good agreement and the insignificant difference between both methods. The obtained percentages of recovery (99-101%) indicate no interference from excipients in formulation matrixes. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Safety of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Safety of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study was written by Lim, Sean H.;Stuart, Beth;Joseph-Pietras, Debora;Johnson, Marina;Campbell, Nicola;Kelly, Adam;Jeffrey, Danielle;Turaj, Anna H.;Rolfvondenbaumen, Kate;Galloway, Celine;Wynn, Thomas;Coleman, Adam R.;Ward, Benjamin;Long, Karen;Coleman, Helen;Mundy, Carina;Bates, Andrew T.;Ayres, Diana;Lown, Robert;Falconer, Janlyn;Brake, Oliver;Batchelor, James;Willimott, Victoria;Bowzyk Al-Naeeb, Anna;Robinson, Lisa;O’Callaghan, Ann;Collins, Graham P.;Menne, Tobias;Faust, Saul N.;Fox, Christopher P.;Ahearne, Matthew;Johnson, Peter W. M.;Davies, Andrew J.;Goldblatt, David. And the article was included in Nature Cancer in 2022.Synthetic Route of C16H21Cl2N3O2 The following contents are mentioned in the article:

Patients with hematol. malignancies are at increased risk of severe COVID-19 outcomes due to compromised immune responses, but the insights of these studies have been compromised due to intrinsic limitations in study design. We present the PROSECO prospective observational study (NCT04858568) on 457 patients with lymphoma that received 2 or 3 COVID-19 vaccine doses. We show undetectable humoral responses following 2 vaccine doses in 52% of patients undergoing active anticancer treatment. Moreover, 60% of patients on anti-CD20 therapy had undetectable antibodies following full vaccination within 12 mo of receiving their anticancer therapy. However, 70% of individuals with indolent B-cell lymphoma displayed improved antibody responses following booster vaccination. Notably, 63% of all patients displayed antigen-specific T-cell responses, which increased after a 3rd dose irresp. of their cancer treatment status. Our results emphasize the urgency of careful monitoring of COVID-19-specific immune responses to guide vaccination schemes in these vulnerable populations. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Synthetic Route of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Synthetic Route of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group was written by Raa, Doreen G. Te;van der Straten, Lina;van Gelder, Michel;Kersting, Sabina;Levin, Mark-David;Mous, Rogier;van der Straaten, Hanneke M.;Nijziel, Marten R.;van der Spek, Ellen;Posthuma, Eduardus F. M.;Visser, Hein P. J.;van der Klift, Marjolein;de Heer, Koen;Bellido, Mar;Doorduijn, Jeanette K.;Bruns, Anke H. W.;Raijmakers, Reinier A. P.;Kater, Arnon P.. And the article was included in Leukemia & Lymphoma in 2022.Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

Management of patients with chronic lymphocytic leukemia (CLL) is changing due to considerable advances in the therapeutic armamentarium, and new therapies will possibly continue to emerge in the near future. Therefore, the CLL working group of the Dutch-Belgium Haemato-Oncol. Cooperative Group for Adults in the Netherlands (HOVON) necessitated revising the Dutch CLL guidelines. The current guideline is based on the expert opinion of the HOVON CLL working group members and focusses on well-designed clin. trials taking into account efficacy with special emphasis on toxicity, treatment duration and treatment intensity. This article provides recommendations on diagnosis, treatment strategies in front-line and relapsed setting and provides supportive care measurements during novel-based therapies as well as for infectious CLL-related complications. The recommendations presented here are intended to provide guidance for the management of CLL patients in the Netherlands, and take into account the availability of treatment strategies at the time of this publication. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial was written by Cochrane, Tara;Enrico, Alicia;Gomez-Almaguer, David;Hadjiev, Evgueniy;Lech-Maranda, Ewa;Masszi, Tamas;Nikitin, Eugene;Robak, Tadeusz;Weinkove, Robert;Wu, Shang-Ju;Sail, Kavita R.;Pesko, John;Pai, Madhavi;Komlosi, Viktor;Anderson, Mary Ann. And the article was included in Leukemia & Lymphoma in 2022.Category: imidazoles-derivatives The following contents are mentioned in the article:

Venetoclax, a potent B-cell lymphoma-2 (BCL-2) inhibitor, has demonstrated clin. efficacy in chronic lymphocytic leukemia (CLL). VENICE II is an open-label, single-arm, phase 3b study (NCT02980731) evaluating the impact of venetoclax monotherapy (400 mg once daily) for ≤2 years on health-related quality of life (HRQoL) of patients with relapsed/refractory CLL. The primary endpoint was mean change in the global health status (GHS)/quality of life (QoL) subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) from baseline to Week 48. Overall, 210 patients received ≥1 dose of venetoclax; median treatment duration was 67.4 wk. The primary endpoint was met with mean improvement of +9.3 points (n = 156, 95% confidence interval 6.1-12.5; p = .004) in GHS/QoL. At Week 48, clin. meaningful improvements were observed for role functioning, fatigue, and insomnia domains of EORTC QLQ-C30, suggesting venetoclax monotherapy has a pos. impact on HRQoL. No new safety signals were reported. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Category: imidazoles-derivatives).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Category: imidazoles-derivatives

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab was written by Hsu, Andrew;Kurt, Habibe;Zayac, Adam S.;Olszewski, Adam J.. And the article was included in Leukemia & Lymphoma in 2022.Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

We examined outcomes of 244 patients with marginal zone lymphoma (MZL) diagnosed in 2010-2020, of which 25 (10%) expressed CD5. CD5 expression was present in 22% of splenic, 8% of nodal, and 5% of extranodal MZL, and showed frequent blood/bone marrow involvement, elevated lactate dehydrogenase, and TP53 deletions. CD5 expression was not associated with progression-free or overall survival, but it conferred a significantly higher risk of histol. transformation (22% vs. 4% at 5 years, p = 0.002). Among patients receiving first-line rituximab monotherapy, CD5 expression was associated with lower response rate (30% vs. 77%, p = 0.006), PFS (25% vs. 45% at 3 years, p = 0.003) and OS (44% vs. 77%, p = 0.010), whereas CD5 status did not significantly affect outcomes of patients receiving bendamustine with rituximab (P for interaction = 0.012 for progression-free survival). CD5-pos. MZL may have a propensity to leukemic dissemination, histol. transformation, and may derive benefit from first-line bendamustine/rituximab rather than rituximab alone. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Stereoselective and nonstereoselective pharmacokinetics of rabeprazole – an overview was written by Dash, Ranjeet Prasad;Rais, Rana;Srinivas, Nuggehally R.. And the article was included in Xenobiotica in 2018.Electric Literature of C18H20N3NaO3S The following contents are mentioned in the article:

A review. Proton pump inhibitors have been extensively used for the treatment of ailments due to increased gastric acid secretion such as peptic ulcers, gastroesophageal reflux disease, etc. There are several approved drugs in the proton pump inhibitor class with the latest entries representing single enantiomer drugs of the previously approved racemic drugs. Despite having a high degree of structural resemblance, rabeprazole, was shown to possess some unique differentiation from other drugs in the class. One of the key distinguishing features of rabeprazole was related to the lesser involvement of polymorphic metabolism in its pharmacokinetic disposition. The review was aimed to provide pharmacokinetic data of rabeprazole from several clin. studies including drug-drug interaction studies where rabeprazole was either a perpetrator drug or victim drug. Addnl. perspectives on therapy considerations due to the unique metabolic disposition of rabeprazole including the possible issues related to chirality were provided. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Electric Literature of C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Electric Literature of C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study was written by Aussedat, Guillaume;Maucort-Boulch, Delphine;Rey, Philippe;Safar, Violaine;Karlin, Lionel;Elsensohn, Mad Helenie;Bachy, Emmanuel;Lebras, Laure;Favier, Bertrand;Vantard, Nicolas;Ghergus, Dana;Golfier, Camille;Sesques, Pierre;Lazareth, Anne;Lequeu, Helene;Ferrant, Emmanuelle;Salles, Gilles;Nicolas-Virelizier, Emmanuelle;Ghesquieres, Herve. And the article was included in Leukemia & Lymphoma in 2022.Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

We retrospectively reviewed for 72 relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem-cell transplantation (ASCT) treated between 2004 and 2017, efficacy and safety profile of rituximab (375 mg/m²) in combination with etoposide (300 mg/m²) and ifosfamide (1500 mg/m²) at 2, 3, or 4-wk intervals. Median age was 79 years (range, 64-92). The median number of previous line was 1 (range 1-8). Patients received a median of six cycles (1-12). Fourteen patients (19%) presented partial and 14 complete responses (19%). Among the 369 cycles, nine patients developed febrile neutropenia (13%), 14 a grade 3-4 neutropenia (19%), 7 a grade 3-4 thrombocytopenia (10%) without grade 3-4 non-hematol. toxicity. With a median follow up of 7.8 mo, the median progression-free survival, overall survival, and duration of response were 4.4 mo, 9.4 mo, and 12 mo, resp. This regimen represents a therapeutic option in R/R DLBCL patients ineligible to ASCT. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Repurposing of pharmaceutical drugs by high-throughput approach for antihypertensive activity as inhibitors of angiotensin-converting enzyme (ACE) using HPLC-ESI-MS/MS method was written by Bhatti, Muhammad Salman;Asiri, Yahya Ibrahim;Uddin, Jalal;El-Seedi, Hesham R.;Musharraf, Syed Ghulam. And the article was included in Arabian Journal of Chemistry in 2021.Electric Literature of C18H20N3NaO3S The following contents are mentioned in the article:

Angiotensin-converting enzyme (ACE) plays an important role in regulating blood pressure in the body by converting angiotensin-I into angiotensin-II. It is the basic component of Renin angiotensin aldosterone system (RAAS), imbalance of RAAS may leads to many cardiovascular and renal diseases. There are many marketed available drugs for the inhibition of ACE, but prolonged use of some drugs may cause the progressive side effects. Repurposing of existing drugs can be a way to find new inhibitors of ACE. In this study, a high-throughput and sensitive method of HPLC-ESI-QqQ-MS with good reproducibility (%RSD < 9.98) and linearity (R2 = 0.999) was used to investigate the 77 com. drugs for their inhibitory potential as antihypertensive drugs. Among these drugs, 41 drugs were found active and 36 of them showed moderate to good inhibition with lowest IC₅₀ = 272 μM. This study showed that different pharmaceutical drugs can also be used as ACE inhibitor after necessary clin. trials or validation. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Electric Literature of C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Electric Literature of C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem